GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Medistim ASA (OSL:MEDI) » Definitions » EBIT

Medistim ASA (OSL:MEDI) EBIT : kr138.8 Mil (TTM As of Mar. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Medistim ASA EBIT?

Medistim ASA's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was kr35.7 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was kr138.8 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Medistim ASA's annualized ROC % for the quarter that ended in Mar. 2024 was 31.24%. Medistim ASA's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 69.27%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Medistim ASA's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 4.42%.


Medistim ASA EBIT Historical Data

The historical data trend for Medistim ASA's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medistim ASA EBIT Chart

Medistim ASA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 91.48 91.75 114.25 146.17 135.36

Medistim ASA Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41.01 43.05 33.59 26.50 35.65

Competitive Comparison of Medistim ASA's EBIT

For the Medical Devices subindustry, Medistim ASA's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medistim ASA's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Medistim ASA's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Medistim ASA's EV-to-EBIT falls into.



Medistim ASA EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr138.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medistim ASA  (OSL:MEDI) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Medistim ASA's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=128.272 * ( 1 - 20.49% )/( (294.761 + 358.088)/ 2 )
=101.9890672/326.4245
=31.24 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=505.718 - 64.875 - ( 146.082 - max(0, 94.284 - 391.566+146.082))
=294.761

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Medistim ASA's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=142.604/( ( (57.306 + max(153.213, 0)) + (61.611 + max(139.599, 0)) )/ 2 )
=142.604/( ( 210.519 + 201.21 )/ 2 )
=142.604/205.8645
=69.27 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(74.303 + 145.391 + 19.419) - (64.875 + 0 + 21.025)
=153.213

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(68.084 + 157.373 + 0) - (0 + 0 + 85.858)
=139.599

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Medistim ASA's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=138.792/3143.109
=4.42 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medistim ASA EBIT Related Terms

Thank you for viewing the detailed overview of Medistim ASA's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Medistim ASA (OSL:MEDI) Business Description

Traded in Other Exchanges
Address
Okernveien 94, Oslo, NOR, 0579
Medistim ASA is a medical device company. It is engaged in researching, developing, producing, distributing and sales of medical equipment through its own business or through participation in other companies, as well related activities. The company's business is focused on cardiac and vascular surgery. The group operates in the USA, Europe, Asia and the Rest of the World. The firm's activity is split into three strategic operating units, Lease of equipment; Lease of equipment and Distribution and sales of third-party products.

Medistim ASA (OSL:MEDI) Headlines